共 364 条
[1]
Liu E(2004)Analysis of the trend of incidence of malignant tumors in Shanghai region (from years 1972–1999) Tumor 24 11-15
[2]
Xiang Y(2006)The treatment of multiple myeloma: current status and progress Chin J Pract Intern Med 26 886-888
[3]
Jin F(2008)Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516-2520
[4]
Zhou S(2008)China treatment guideline for multiple myeloma Chin J Intern Med 47 869-872
[5]
Sun L(2007)Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma N Engl J Med 357 2123-2132
[6]
Fang R(2007)Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl J Med 357 2133-2142
[7]
Yuan Z(2010)Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma Int J Hematol 92 118-126
[8]
Gao L(2002)Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma Blood 100 3063-3067
[9]
Gao Y(2010)Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Lancet Oncol 11 29-37
[10]
Qiu L(2010)Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment Eur J Haematol 85 1-5